Plus   Neg

Pharma News Today (TRVN,FPRX,TTPH)

Trevena, Inc. (TRVN) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for OLINVO (oliceridine), a moderate to severe acute pain reliever injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018.

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.

Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant infections, announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous eravacycline for the treatment of complicated intra-abdominal infections.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT